Research Article
Quantitative Analysis of Favipiravir by HPLC: Development and Validation
Table 5
Favipiravir sensitivity showing LOD and LOQ.
| Conc (%) | Conc. (ppm) | Injection area repetition 1 | Injection area repetition 2 | Injection area repetition 3 | Average area |
| 5.0 | 0.0250 | 0.018 | 0.019 | 0.018 | 0.018 | 12.5 | 0.0625 | 0.046 | 0.045 | 0.047 | 0.046 | 25.0 | 0.1250 | 0.093 | 0.094 | 0.092 | 0.093 | 50.0 | 0.2500 | 0.185 | 0.186 | 0.187 | 0.186 | 100.0 | 0.5000 | 0.374 | 0.373 | 0.373 | 0.373 | 150.0 | 0.7500 | 0.562 | 0.558 | 0.56 | 0.560 | 200.0 | 1.0000 | 0.746 | 0.747 | 0.747 | 0.747 | STEYX | 0.001 | 0.001 | 0.001 | 0.001 | Slope | 0.7480 | 0.7464 | 0.7474 | 0.747 | LOQ (ppm) | 0.0156 | 0.0151 | 0.0084 | 0.0130 | LOD (ppm) | 0.0051 | 0.0050 | 0.0028 | 0.0043 |
|
|